Table 1. wt1 Expression in AML According... | American Society of Hematology

Table 1.

wt1 Expression in AML According to FAB Subtype and Age

	wt1⁺ Patients	%
AML, total^*	124/161	77.0
AML, de novo	85/114	74.6
AML, after MDS	11/15	73.3
AML, first relapse^*	28/32	87.5
FAB subtype of de novo AML
M0	3/3	100.0
M1	8/9	88.9
M2	29/39	74.4
M3	7/8	87.5
M4	28/36	77.8
M5^†	6/15	40.0
M6	3/3	100.0
ND	1/1
Age <60 yr	70/92	76.1
Age >60 yr	36/47	76.6

	wt1⁺ Patients	%
AML, total^*	124/161	77.0
AML, de novo	85/114	74.6
AML, after MDS	11/15	73.3
AML, first relapse^*	28/32	87.5
FAB subtype of de novo AML
M0	3/3	100.0
M1	8/9	88.9
M2	29/39	74.4
M3	7/8	87.5
M4	28/36	77.8
M5^†	6/15	40.0
M6	3/3	100.0
ND	1/1
Age <60 yr	70/92	76.1
Age >60 yr	36/47	76.6

In M5 AMLs the frequency of wt1 expression was significantly reduced (P < 0.0025). The weakly positive wt1 patients were grouped with the wt1-positive patients.

Abbreviation: ND, not defined.

Twenty-two patients included were investigated at the time of diagnosis and first relapse.

†

P < .0025.

View Large

This Feature Is Available To Subscribers Only